DOC1 Activators
DOC1 activators are a class of chemical compounds known for their ability to interact with and modulate the function of DOC1, a protein that can be an integral component of various cellular processes. The term DOC1 typically refers to a protein that is a part of the anaphase-promoting complex/cyclosome (APC/C), which is an essential regulator of the cell cycle. APC/C is a multi-subunit E3 ubiquitin ligase that targets cell cycle regulators for degradation, thus ensuring proper cell division and maintaining genomic integrity. Activators of DOC1 function by influencing the activity of the APC/C complex, often by enhancing its ability to ubiquitinate its substrate proteins. The chemical structure of DOC1 activators can be diverse, reflecting the versatility needed to interact with the complex architecture of the APC/C and DOC1. The precise mechanisms by which these activators work can involve direct binding to DOC1 or inducing conformational changes in the APC/C that promote its interaction with substrates.
The study of DOC1 activators is grounded in the biochemistry and cell biology of the cell cycle. The specificity of these compounds often hinges on their ability to modulate the activity of the APC/C in a controlled manner, which requires a detailed understanding of the structural aspects of the complex and its interaction with DOC1. Research into DOC1 activators frequently involves the use of biochemical assays to measure the activity of the APC/C in the presence of these compounds, as well as structural biology techniques to elucidate how these activators interact with their molecular targets. The design of DOC1 activators may involve structure-activity relationship (SAR) studies, which help in refining the efficacy and selectivity of these compounds. Furthermore, the development of high-throughput screening methods has facilitated the discovery of novel activators by allowing the rapid assessment of large libraries of potential compounds. Through these methods, researchers can identify molecules that have a significant effect on the function of DOC1 within the APC/C, providing insights into the regulation of the cell cycle at a molecular level.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing levels of cAMP. If DOC1's activity is cAMP-dependent, elevated cAMP levels would enhance DOC1 activity by furthering cAMP-dependent signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC). If DOC1 is downstream of PKC in a signaling pathway, PMA-induced activation of PKC can lead to the phosphorylation and subsequent activation of DOC1. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. If DOC1 is calcium-sensitive, the increase in intracellular calcium from ionomycin can enhance DOC1's activity by promoting its interaction with calcium/calmodulin-dependent processes. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin activates the PI3K/Akt pathway, which is involved in cell survival and growth. If DOC1 functions are enhanced by Akt phosphorylation, insulin would indirectly increase DOC1 activity through this pathway. | ||||||
(±)-S-Nitroso-N-acetylpenicillamine | 79032-48-7 | sc-200319B sc-200319 sc-200319A | 10 mg 20 mg 100 mg | $74.00 $114.00 $374.00 | 18 | |
SNAP releases nitric oxide (NO), which can activate guanylate cyclase and increase cGMP levels. If DOC1 activity is modulated by cGMP-dependent protein kinases, SNAP would enhance DOC1 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP. If DOC1 is regulated by these cyclic nucleotides, the inhibition of their degradation by IBMX would enhance DOC1 activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cell-permeable cAMP analog that directly activates cAMP-dependent pathways. If DOC1 is activated by such pathways, db-cAMP would enhance its activity by mimicking the effects of cAMP. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is an inhibitor of protein phosphatases PP1 and PP2A. If DOC1 is negatively regulated by dephosphorylation, the inhibition of these phosphatases by okadaic acid could enhance the phosphorylated (active) state of DOC1. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium inhibits glycogen synthase kinase-3 (GSK-3). If DOC1 activity is enhanced by the inhibition of GSK-3, lithium chloride can indirectly increase DOC1 activity by preventing GSK-3 from negatively regulating DOC1 or its upstream activators. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases like JNK. If DOC1 is activated as part of a cellular stress response, anisomycin may enhance DOC1 activity indirectly through the activation of stress response pathways. | ||||||